DIABETES: 2021 Clinical Focus Collection

Clinical Focus Collection: Diabetes

Table of Contents

Videos – Expert Interviews

At ADA 2021, John Buse, MD, PhD, says US Must Focus on Control of Obesity, Other T2D Risk Factors

Inside GRADE: Exec Committee Member John Buse, MD, PhD, Toplines Study Results, Calls for More Head-to-Head Research

John B. Buse, MD, PhD
Distinguished Professor, Chief, Division of Endocrinology, Director, Diabetes Center, Executive Associate Dean for Clinical Research
University of North Carolina School of Medicine at Chapel Hill

Tom Martens, MD, Talks about the Vision for CGM as Part of Primary Care for Type 2 Diabetes

MOBILE Study Findings on CGM vs BGM in T2 Diabetes

CGM vs SMBG in Primary Care: What Does the T2D Evidence Say?

Thomas Martens, MD
Medical Director, Park Nicolette International Diabetes Center
HealthPartners Institute
Minneapolis, MN

A Weight-centric Approach to Obesity with T2D: How Pharmacotherapy Works

Silvana Pannain, MD
Associate Professor of Medicine
Section of Endocrinology, Diabetes and Metabolism
University of Chicago Medicine
Director, Chicago Weight

Brigham & Women's Diabetes Expert Highlights 2020 Research

Marie McDonnell, MD
Director, Brigham & Women's Diabetes Program, Brigham & Women's Hospital
Associate Professor of Medicine, Harvard Medical School
Boston, MA

Semaglutide 2.4 mg for Obesity: Investigator Toplines Clinical Trial Results, Focused on Primary Care

Robert F. Kushner, MD
Professor of Medicine & Medical Education, Northwestern University Feinberg School of Medicine
Director, Center for Lifestyle Medicine
Chicago, IL

How to Optimize SGLT2 Inhibitor Therapy in Primary Care: An Expert Interview

SGLT-2 Inhibitors: Mikhail Kosiborod, MD, Highlights the Journey to Pluripotency

Mikhail Kosiborod, MD
Professor of Medicine
University of Missouri Kansas City
Vice President, Research
Saint Luke’s Health System
Executive Director, Cardiometabolic Center Alliance
Director, Cardiometabolic Research and Co-director
Haverty Cardiometabolic Center of Excellence
Saint Luke’s Mid America Heart Institute
Kansas City, MO

Keep NASH on the Tip of your Diagnostic Tongue

Seth J. Baum, MD
Founder, Chief Medical Officer, Excel Medical Clinical Trials, LLC
Clinical Affiliate Professor, Biomedical Science, Department of Integrated Medical Sciences, Charles E. Schmidt College of Medicine
Boca Raton, FL

Heart Failure, Renal Disease, CV Risk Research is on Fire

George L. Bakris, MD
Professor of Medicine
Director, American Society of Hypertension Comprehensive Hypertension Center
University of Chicago Medicine
Chicago, IL

Tests of Clinical Knowledge

• 8 Questions on Diabetes Drugs for Cardioprotection
• 8 Questions on T2 Diabetes Risk Assessment Using Prediabetes Subphenotypes
• SGLT2 Inhibitors: 4 Questions Go Back to Basics
• A Diabetes Prevention Program Quiz: By the Numbers
• A Test of CKD IQ: 10 Questions for Primary Care Clinicians

Slideshows - Education At-a-Glance

• Diabetes Management in CKD: 10 Top Takeaways from KDIGO 2020
• Prediabetes Subphenotyping: A Novel Approach to Type 2 Diabetes Prevention
• How to Slow CKD Progression: Treatment Essentials for Primary Care
• NAFLD & NASH in Primary Care: Facts, Definitions, & Figures in Brief

Conference Roundup

American Diabetes Association

• Clinical Trial Updates at the ADA Scientific Sessions 2021: A few primary care musts
• ADA 2021 Symposia Focus on Health Disparities Exposed and Deepened by COVID-19 Pandemic
• Study Finds Hospitalization Rates for New-onset Pediatric T2D Doubled During Pandemic
• Renoprotection with Finerenone Consistent Regardless of SGLT2 Inhibitor Use
• Novel Agent Tirzepatide Superior to Semaglutide in Reducing A1c, Body Weight in Type 2 Diabetes
• Renal, CV Protection in FIDELIO-CKD Unaffected by Baseline GLP-1 RA Use
• Efpeglenatide Reduces CV Risk, Progression of Renal Disease in High-risk T2D Population
• Use of Dapagliflozin Decreases Risk of Diabetes in Patients with CKD
• GLP-1 RA, Insulin More Effective Second-line vs Sulfonylurea, DPP-4 Inhibitor for T2D
• Baseline Insulin Use May not Impact Benefits of Finerenone in Patients with CKD, T2D

European Association for the Study of Diabetes

• Women with T2D Less Likely to Receive Guideline-recommended Cardiovascular Care vs Men
• Sustained Weight Loss May Reverse CV Risk Factors Linked to Obesity, Study Shows
• COVID-19 Lockdown Had Significant, Yet Varying, Impact on Glycemic Control
• SUSTAIN-10 Post-hoc Analysis Suggests Additive Benefits for GLP-1 RA-SGLT-2i Combination

FDA Decisions

• FDA Grants Insulin Lispro-aabc Label Expansion for use in Insulin Pumps
• Novel “Smart” Pen Cap for Insulin Dosing Receives FDA Clearance in Patients with Diabetes
• FDA Approves Dapagliflozin to Treat Chronic Kidney Disease in Adults at Risk of Progression, Regardless of Diabetes Status
• Finerenone Approved as First-in-Class Treatment for Chronic Kidney Disease Associated with Type 2 Diabetes
• Empagliflozin FDA-approved for Heart Failure with Reduced Ejection Fraction